Exact Sciences (EXAS) Misses Q1 EPS by 1c, Revs Beat; Raises Outlook

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.66), $0.01 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $162 million versus the consensus estimate of $153.04 million.

GUIDANCE:

Exact Sciences sees FY2019 revenue of $725-740 million, versus prior of $710-$730 million the consensus of $729.5 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30